RxDoctor Payments DataLook up a doctor →

Neil Schaffner, MD

Endocrinology, Diabetes & Metabolism · Opelika, ALNPI 1184684953

Payments from drug & device makers

$641,804in general payments, 2019–2025

Across 1,581 payments — averaging $405.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$435K
  • AstraZeneca$129K
  • Sanofi-aventis U.S. LLC$65K
  • Abbott$5K
  • Novo Nordisk$1K
  • Medtronic$1K
  • plus $5K from 45 others
$113in research payments, 2019–2025

Across 3 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk$38
  • GSK$38
  • AstraZeneca$38

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC763$435,461
AstraZeneca(2 entities)223$128,647
Sanofi-aventis U.S. LLC146$65,098
Abbott73$5,312
Novo Nordisk74$1,198
Medtronic(2 entities)20$1,164
Xeris Pharmaceuticals, Inc.48$671
Mannkind Corporation22$396
AbbVie21$310
Ascendis Pharma Endocrinology Inc16$302
Radius Health, Inc.14$300
Insulet Corporation12$277
Tandem Diabetes Care, Inc.14$269
Corcept Therapeutics11$217
Amgen(2 entities)14$197
Ultragenyx Pharmaceutical Inc.10$176
Boehringer Ingelheim12$164
Bayer7$147
Amneal Pharmaceuticals LLC7$118
Dexcom, Inc.6$114
Johnson & Johnson4$114
Merck7$87
Tolmar, Inc.6$86
Lifescan, Inc.4$78
BETA Bionics, Inc.3$77
Shire North American Group Inc5$70
Zealand Pharma US, Inc.5$66
IBSA Pharma Inc.3$57
Esperion Therapeutics, Inc.3$54
Intuity Medical Inc2$52
Amphastar Pharmaceuticals, Inc.2$46
Tolmar Pharmaceuticals, Inc.2$46
Neurocrine Biosciences, Inc.2$41
Amarin Pharma, Inc.2$37
Novartis2$32
Hologic Sales And Service, LLC1$27
Rhythm Pharmaceuticals, Inc.1$26
Amryt Pharma Holdings Ltd1$25
EUSA Pharma (US) LLC1$25
Recordati_rare_diseases_inc.1$25
Ionis Pharmaceuticals, Inc.1$22
BD1$22
Kyowa Kirin, Inc.1$20
Embecta Corp.1$19
Eton Pharmaceuticals, Inc.1$18
Soleno Therapeutics, Inc.1$18
Sequel Med Tech, LLC1$16
Takeda Pharmaceuticals U.S.A., Inc.1$15
Mckesson Patient Care Solutions Inc.1$15
Biomarin Pharmaceutical Inc.1$15
Vivus LLC1$12

How this compares

$641,804 in reported general payments places this provider in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama →

Medicare billing

Part B allowed, 2024
$31,493
Medicare patients
243
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Opelika

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →